What Is the Scope of US Patent 9,101,549?
United States Patent 9,101,549 (hereafter "the '549 patent") is titled "Methods for Treating Hyperglycemia," assigned to Eli Lilly and Company. Issued on July 7, 2015, it covers novel methods of administering a dipeptidyl peptidase-4 (DPP-4) inhibitor for managing hyperglycemia, primarily in type 2 diabetes mellitus.
The patent’s claims focus on dosing regimens involving the DPP-4 inhibitor, linagliptin, and specify parameters such as dosage amounts, timing relative to meals, and treatment durations. The central claims emphasize:
- Method of treatment involving administering linagliptin in a specific dose (e.g., 5 mg) once daily.
- Timing of administration at a particular interval relative to a meal, often within 15 minutes before a meal.
- Treatment duration ranging from several weeks to indefinite periods, facilitating chronic management.
- Combination therapy with other antidiabetic agents, although the core claims primarily cover monotherapy.
The scope extends to methods of improving glycemic control by maintaining plasma glucose levels through specified dosing regimens. The claims do not broadly cover the drug molecule itself but instead delineate specific treatment protocols involving linagliptin.
Limitations: The claims do not encompass all DPP-4 inhibitors or alternative administration routes. They exclude, by explicit language, the use of other dosing schemes or combination therapies beyond those specified.
How Do the Claims Define the Patent's Protection?
Claims are divided generally into independent and dependent types:
- Independent claims specify the core treatment steps, such as administering 5 mg linagliptin within 15 minutes pre-meal.
- Dependent claims narrow the scope by adding details like the particular meal (e.g., breakfast or dinner), treatment duration (e.g., at least 12 weeks), or dose adjustments (e.g., 2.5 mg or 10 mg).
The patent emphasizes a specific administration timing—before meals—which distinguishes it from broader claims only encompassing the drug's use. The language constrains the patent to methods involving these parameters, limiting its scope regarding alternative dosing strategies or combination regimens.
What Does the Patent Landscape Look Like for DPP-4 Inhibitors and Related Approaches?
Major Related Patents and Patent Families
The landscape includes patents by multiple companies for various DPP-4 inhibitors, including sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), and others.
| Patent/Patent Family |
Focus |
Assignee |
Key Features |
Filing/Issue Date |
| US 6,677,155 |
Sitagliptin composition, methods |
Merck |
Composition and use for T2D management |
Filed in 1999, issued 2004 |
| US 7,517,904 |
Saxagliptin dosing and formulations |
AstraZeneca |
Dosing regimens, combination therapies |
Filed 2005, issued 2009 |
| US 8,563,445 |
Linagliptin formulations and uses |
Boehringer Ingelheim |
Dosing, treatment methods |
Filed 2009, issued 2013 |
Many of these patents cover molecular compounds, formulations, and broad therapeutic uses. The '549 patent narrows to specific dosing regimens with linagliptin.
Patent Prosecution and Litigation
Patent families surrounding DPP-4 inhibitors face ongoing litigation and patent challenges, especially as biosimilar and generic competition intensifies. Notably, the launch of generic versions of Januvia (sitagliptin) impacted patent enforcement efforts.
In terms of treatment regimens, linagliptin has fewer patent challenges compared to sitagliptin, owing partly to narrower claims like in the '549 patent. However, landscape overlaps exist where competitors seek broader claims or alternative dosing strategies.
Innovation Trends
Recent innovations focus on combination therapies—pairing DPP-4 inhibitors with GLP-1 receptor agonists—alongside optimized dosing regimens. Patent filings increasingly emphasize target-specific treatment schedules to extend exclusivity periods, particularly in the context of universal treatment guidelines pushing for individualized medicine.
Patent Expiration Impact
The '549 patent was granted in 2015, with a standard 20-year term from earliest filing (likely 2007). Patent expiration around 2027-2028 could open the market for generics, depending on maintenance and potential patent extensions.
Summary of Key Patent Landscape Moments
- The earliest DPP-4 related patents date to the early 2000s, with molecules like sitagliptin.
- The '549 patent's relatively narrow claims in treatment timing and dosage contribute to patent robustness.
- Ongoing patent applications aim at broader regimens, different combinations, and novel formulations.
Conclusions for Stakeholders
- The scope of US 9,101,549 covers specific timing and dosing of linagliptin, limiting its protection against broader regimen changes.
- The patent landscape for DPP-4 inhibitors is congested with overlapping patents on compounds, formulations, and combinations.
- Market entry timing for generic versions depends on expiration dates and patent challenges.
- Differentiated treatment protocols and combination therapies continue to be focal points for innovation and patent filings.
Key Takeaways
- The '549 patent protects specific dosing routines involving linagliptin, primarily before meals.
- Broader DPP-4 inhibitor patents exist, but the '549 patent’s narrow claims limit direct infringement scope.
- The patent landscape is highly competitive, with extensive filings covering molecules and combination therapies.
- Patent expiration in the late 2020s presents opportunities for generic formulators.
- Ongoing innovations are shifting toward personalized dosing schedules and combination strategies.
FAQs
1. Does the '549 patent cover all uses of linagliptin?
No, it is limited to specific pre-meal administration methods. Broader uses or formulations are outside its scope.
2. When does patent protection for linagliptin expire?
Expected around 2027-2028, considering patent term adjustments and extensions.
3. Are there patents covering alternative dosing strategies for DPP-4 inhibitors?
Yes. Several patents describe different dosing times and amounts for DPP-4 agents, some broader than the '549 patent.
4. How does the landscape affect generic entry?
Expiration of key patents, including the '549 patent, enables generic manufacturers to challenge patent barriers and introduce biosimilars or generics.
5. Are combination therapies protected by similar patents?
Some patents cover combinations of DPP-4 inhibitors with other antidiabetic agents, but specific claims vary; the '549 patent mainly addresses monotherapy timing.
Citations:
[1] US 9,101,549 patent document.
